NEW HAVEN, Conn., April 3, 2014 – Melinta Therapeutics today announced that Mary Szela, the Company’s chief executive officer, will be presenting a corporate update at Needham & Company’s 13th annual Healthcare Conference. Melinta’s presentation will take place on Tuesday, April 8, 2014 at 9:20am Eastern Time at the Westin Grand Central Hotel in New York, NY.
Needham & Company’s annual Healthcare Conference is a forum for institutional investors and venture capital firms to hear the latest updates from both public and private companies in the Biotechnology, Specialty Pharmaceuticals, Medical Technology and Diagnostics sectors. Attendance at this conference is by invitation only.
About Melinta Therapeutics
Melinta Therapeutics is dedicated to the discovery, development and commercialization of groundbreaking antibiotics to overcome drug-resistant, life-threatening infections. The need for new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. To meet this need, Melinta Therapeutics is rapidly progressing its late-stage investigational antibiotic, delafloxacin, which is currently in Phase 3 development for acute bacterial skin and skin structure infections (ABSSSI) and uncomplicated gonorrhea. A key initiative at Melinta is to develop, through the application of Nobel Prize-winning science, a new class of antibiotics designed to overcome the drug-resistant ESKAPE pathogens known to cause serious hospital infections. Melinta Therapeutics is privately held and backed by lead investor Vatera Healthcare Partners among other venture firms. The company is headquartered in New Haven, CT with offices in Lincolnshire, IL.
For more information, visit www.melinta.com.